Dec 19 Ionis Pharmaceuticals Inc said
on Monday its metabolic disorder drug for severe
hypertriglyceridemia, characterized by elevated levels of a type
of fat in the blood, met the main goal in a late-stage study.
The drug, volanesorsen, brought about a statistically
significant 71.2 percent mean reduction in triglycerides after
13 weeks of treatment, compared with 0.9 percent in those who
got the placebo, the company said.
Patients in the trial had two rare metabolic disorders:
familial chylomicronemia syndrome (FCS) and familial partial
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by